Cover Image

A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4

Dipeptidyl peptidase-4 (DPP-4) inhibitors not only improve impaired glucose tolerance in diabetes, but also have pleiotropic extra-pancreatic effects such as preconditioning effect for myocardial ischemia-reperfusion injury. Here, we investigated the anti-remodeling effects of linagliptin, a DPP-4 i...

Full description

Saved in:

Bibliographic Details
Main Authors:	Takehiro Yamaguchi (Author), Ayano Watanabe (Author), Masako Tanaka (Author), Masayuki Shiota (Author), Mayuko Osada-Oka (Author), Soichi Sano (Author), Minoru Yoshiyama (Author), Katsuyuki Miura (Author), Shojiro Kitajima (Author), Shinji Matsunaga (Author), Shuhei Tomita (Author), Hiroshi Iwao (Author), Yasukatsu Izumi (Author)
Format:	Book
Published:	Elsevier, 2019-02-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
by: Tianli Zhang, et al.
Published: (2021)

Association of serum and salivary dipeptidyl peptidase-4 (DPP-4) with oral cancerous and precancerous lesions; an observational diagnostic accuracy study
by: Nayroz Abdel Fattah Tarrad, et al.
Published: (2024)

Impact on decision making framework for medicine purchasing in Chinese public hospital decision-making: determining the value of five dipeptidyl peptidase 4 (DPP-4) inhibitors
by: Yun Bao, et al.
Published: (2021)

Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis
by: Dan Liu, et al.
Published: (2019)

α-Amylase and dipeptidyl peptidase-4 (DPP-4) inhibitory effects of Melicope latifolia bark extracts and identification of bioactive constituents using in vitro and in silico approaches
by: Alexandra Quek, et al.
Published: (2021)

Design, Synthesis and Biological Evaluation of Neogliptin, a Novel 2-Azabicyclo[2.2.1]heptane-Based Inhibitor of Dipeptidyl Peptidase-4 (DPP-4)
by: Ivan O. Maslov, et al.
Published: (2022)

Bullous pemphigoid receiving a novel long‐acting dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor omarigliptin in a patient with type 2 diabetes: A case report
by: Hiroshi Kasamatsu, et al.
Published: (2021)

Population Pharmacokinetic/Pharmacodynamic Analysis of the DPP-4 Inhibitor Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus
by: Yusuke Tadayasu, et al.
Published: (2013)

Renoprotective Effects of DPP-4 Inhibitors
by: Daiji Kawanami, et al.
Published: (2021)

Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl‐peptidase IV inhibitors (DPP4i): Can polypharmacology help explain?
by: Lauren Jones, et al.
Published: (2022)

Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection
by: Praveen P. N. Rao, et al.
Published: (2021)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
by: Jinglong Liu, et al.
Published: (2014)

Differential expression of carcinoembryonic antigen-related cell adhesion molecule-5 (CEACAM5) and dipeptidyl peptidase‐4 (DPP4) with detection of Middle East respiratory syndrome-coronavirus in peripheral blood
by: Abdulkarim Alhetheel, et al.
Published: (2022)

DPP-4 Inhibitor Linagliptin Ameliorates Oxidized LDL-Induced THP-1 Macrophage Foam Cell Formation and Inflammation
by: Wang H, et al.
Published: (2020)

Elucidation of DPP‐4 involvement in systemic distribution and renal reabsorption of linagliptin by PBPK modeling with a cluster Gauss-Newton method
by: Ryo Nakamura, et al.
Published: (2024)

Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes
by: Anand-Krishna Singh, et al.
Published: (2021)

DPP4 as a Potential Candidate in Cardiovascular Disease
by: Chen SY, et al.
Published: (2022)

Non Incretin Effects of DPP-4 Inhibitors: Comparative Study
by: A Shabbir Ali Bhatti, et al.
Published: (2019)

Navigating the chemical space of dipeptidyl peptidase-4 inhibitors
by: Shoombuatong W, et al.
Published: (2015)

The CXCR4 Ligand/Receptor Family and the DPP4 Protease in High-Risk Cardiovascular Patients
by: Jurgen Bernhagen
Published: (2016)

Antioxidant Effects of DPP-4 Inhibitors in Early Stages of Experimental Diabetic Retinopathy
by: Hugo Ramos, et al.
Published: (2022)

Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid,
by: Agoritsa Gravani, et al.
Published: (2022)

UNEXPECTED ADVERSE REACTIONS OF THE DRUGS OF THE GROUP OF INHIBITORS OF DIPEPTIDYL PEPTIDASE-4
by: T. V. Romanova, et al.
Published: (2018)

The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: from to
by: Shian-Ren Lin, et al.
Published: (2019)

DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?
by: Inés Valencia, et al.
Published: (2020)

Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease
by: Schuetz CA, et al.
Published: (2015)

Plasma Nitrate Levels Are Related to Metabolic Syndrome and Are Not Altered by Treatment with DPP-4 Inhibitor Linagliptin: A Randomised, Placebo-Controlled Trial in Patients with Early Type 2 Diabetes Mellitus
by: Melanie Reijrink, et al.
Published: (2021)

Pemphigoid nodularis induced by long-term use of dipeptidyl peptidase-4 inhibitors
by: Natsumi Norikawa, et al.
Published: (2023)

Dipeptidyl Peptidase-4 Inhibitor-associated Bullous Pemphigoid: Recurrence with Epitope Spreading
by: Hiroyuki Takama, et al.
Published: (2018)

Novel Dipeptidyl Peptidase-4-Inhibiting Peptide Derived From β-Lactoglobulin
by: Masayuki Uchida, et al.
Published: (2011)

Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Metabolism and the Possible Underlying Mechanisms
by: Yinqiu Yang, et al.
Published: (2017)

Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors
by: Jong-Mi Seong, et al.
Published: (2021)

Serum dipeptidyl peptidase-4 activity and progranulin level in polycystic ovary syndrome
by: Maryam Abolghasemi, et al.
Published: (2022)

Acquired Haemophilia A in DPP4 Inhibitor-induced Bullous Pemphigoid as Immune Reconstitution Syndrome
by: Seiko Sugiyama, et al.
Published: (2020)

The effects of DPP-4 inhibitor on hypoxia-induced apoptosis in human umbilical vein endothelial cells
by: Akari Nagamine, et al.
Published: (2017)

Dpp4+ interstitial progenitor cells contribute to basal and high fat diet-induced adipogenesis
by: Megan Stefkovich, et al.
Published: (2021)

Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan
by: Motonobu Sakaguchi, et al.
Published: (2012)

The effects of dipeptidyl peptidase-4 on cardiac fibrosis in pressure overload-induced heart failure
by: Masanori Hirose, et al.
Published: (2017)

Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer's disease: a narrative review
by: Xin Jiang, et al.
Published: (2024)

Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus
by: Yayoi Nishida, et al.
Published: (2020)